RT Journal Article
SR Electronic
T1 Statins: a new approach to combat temozolomide chemoresistance in glioblastoma
JF Journal of Investigative Medicine
JO J Investig Med
FD BMJ Publishing Group Ltd
SP 1083
OP 1087
DO 10.1136/jim-2018-000874
VO 66
IS 8
A1 Shahla Shojaei
A1 Javad Alizadeh
A1 James Thliveris
A1 Navid Koleini
A1 Elissavet Kardami
A1 Grant M Hatch
A1 Fred Xu
A1 Sabine Hombach-Klonisch
A1 Thomas Klonisch
A1 Saeid Ghavami
YR 2018
UL http://hw-f5-jim.highwire.org/content/66/8/1083.abstract
AB Patients with glioblastoma multiforme (GBM) have an average life expectancy of approximately 15 months. Recently, statins have emerged as a potential adjuvant cancer therapy due to their ability to inhibit cell proliferation and induce apoptosis in many types of cancer. The exact mechanisms that mediate the inhibitory actions of statins in cancer cells are largely unknown. The purpose of this proceeding paper is to discuss some of the known anticancer effects of statins, while focusing on GBM therapy that includes adjunct therapy of statins with chemotherapeutic agents.